StockNews.com assumed coverage on shares of Evoke Pharma (NASDAQ:EVOK – Free Report) in a research note published on Tuesday. The firm issued a sell rating on the specialty pharmaceutical company’s stock.
Evoke Pharma Stock Up 2.0 %
EVOK stock opened at $4.04 on Tuesday. Evoke Pharma has a 52-week low of $3.44 and a 52-week high of $12.32. The stock’s 50 day moving average is $4.63 and its two-hundred day moving average is $4.75. The company has a market capitalization of $6.00 million, a PE ratio of -0.37 and a beta of 0.16.
Institutional Investors Weigh In On Evoke Pharma
A hedge fund recently bought a new stake in Evoke Pharma stock. Corsair Capital Management L.P. acquired a new position in shares of Evoke Pharma, Inc. (NASDAQ:EVOK – Free Report) during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund acquired 11,667 shares of the specialty pharmaceutical company’s stock, valued at approximately $56,000. Corsair Capital Management L.P. owned about 1.42% of Evoke Pharma as of its most recent SEC filing.
About Evoke Pharma
Evoke Pharma, Inc, a specialty pharmaceutical company, primarily focuses on the development and commercialization of drugs for the treatment of gastroenterological disorders and diseases. It offers Gimoti, a metoclopramide nasal spray to treat symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Read More
- Five stocks we like better than Evoke Pharma
- Best Stocks Under $10.00
- Investing in Small-Cap AI: Powering the Next Tech Revolution
- Financial Services Stocks Investing
- Occidental Petroleum Drops to 52-Week Low: Buy, Sell, or Hold?
- Are Penny Stocks a Good Fit for Your Portfolio?
- Super Micro Computer Is Now NASDAQ Compliant—But Is It a Buy?
Receive News & Ratings for Evoke Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evoke Pharma and related companies with MarketBeat.com's FREE daily email newsletter.
